Physician profile
Jonathan Jassey
NPI 1689887705
$30,964.03
in general payments reported to CMS, 2019-2025
31 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,291 · 2020: $2,469 · 2021: $4,589 · 2022: $313 · 2023: $912 · 2024: $807 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,737 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,655 · Travel and Lodging: $2,865 · Food and Beverage: $2,107 · Gift: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,737.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,655.00 |
| Travel and Lodging | $2,865.25 |
| Food and Beverage | $2,107.38 |
| Gift | $936.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14,809.13 | 2019-2021 | |
| Biomerieux INC | $12,718.62 | 2023-2025 | Biofire Spotfire Respiratory/Sore Throat (R/St) Panel |
| Sekisui Diagnostics LLC | $1,155.00 | 2022-2025 | |
| Corium, LLC | $517.99 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $174.40 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $162.57 | 2023-2024 | Qelbree, Qelbree |
| Aytu Biopharma, INC. | $161.73 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $149.20 | 2020-2025 | Dupixent |
| Grifols USA, LLC | $142.68 | 2023-2025 | Xembify |
| Alk-Abello, INC | $140.97 | 2023-2025 | Grastek, Ragwitek, Odactra |
| Glaxosmithkline, LLC. | $138.63 | 2019-2025 | Nucala, Bexsero |
| Vyne Pharmaceuticals INC. | $122.53 | 2020 | |
| Memed US, INC. | $71.64 | 2025 | Memed Bv |
| Cranial Technologies, INC | $54.06 | 2020-2025 | Doc Band |
| Verrica Pharmaceuticals INC. | $50.20 | 2023-2024 | Ycanth |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cognoa, INC. | $46.40 | 2023 | Canvas Dx |
| Hikma Pharmaceuticals USA | $42.89 | 2024 | Ryaltris |
| Takeda Pharmaceuticals U.S.A., INC. | $34.45 | 2020 | |
| Blueprint Medicines Corporation | $27.75 | 2023 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $27.23 | 2025 | |
| Seqirus USA INC | $25.21 | 2025 | Flucelvax |
| Incyte Corporation | $24.10 | 2024 | Opzelura |
| Shire North American Group INC | $22.22 | 2019 | |
| Kaleo, INC. | $21.88 | 2023 | Auvi-Q |
| Tris Pharma INC | $19.84 | 2019 | |
| Phadia US INC. | $19.10 | 2024 | Immunocap |
| Neos Therapeutics, LP | $18.87 | 2023 | Cotempla Xr-Odt |
| Genentech USA, INC. | $18.85 | 2019 | |
| Lnhc, INC | $17.39 | 2025 | Zelsuvmi |
| Aimmune Therapeutics, INC. | $15.29 | 2023 | |
| Ironshore Pharmaceuticals INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Jassey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.